ETF Data
IBB ETF Data
Fund Profile · Snapshot Metrics · Exposure · Technicals · Risk
IBBiShares Biotechnology ETF
Financial Services / Asset Management
Low Priority
Above Peers
Latest quote
- Momentum77
- Value37
- Quality60
- Risk resilience57
- Sentiment—
ETF Data Overview
ETF pages show fund-native profile, cost, size, liquidity, exposure, technical, and risk evidence.
ETF Snapshot Data
Updated Oct 29, 2026.
| Field | Value |
|---|---|
| Fund name | iShares Biotechnology ETF |
| Issuer | IShares |
| Asset class | Equity |
| Primary exposure | Biotechnology (87.45%) |
| Domicile | US |
| Inception date | Feb 5, 2001 |
| NAV currency | USD |
| CUSIP | — |
| ISIN | US4642875565 |
| Field | Value |
|---|---|
| Price | $217.61 |
| Fund size | $11.52B |
| Expense ratio | 0.44% |
| Holdings count | 247 |
| NAV | $217.99 |
| Average volume | 1.64M |
| Distribution yield | 0.16% |
| AIQ Score | 57/100 |
ETF Holdings
Reported holdings from the latest ETF holder snapshot.
- VRTXVERTEX PHARMACEUTICALS7.94%
- AMGNAMGEN INC7.92%
- GILDGILEAD SCIENCES7.38%
- REGNREGENERON PHARMACEUTICALS5.95%
- ARGXARGENX SE ADR3.80%
- Rest of fund67.01%
| Symbol | Holding | Weight | Market value |
|---|---|---|---|
| VRTX | VERTEX PHARMACEUTICALS | 7.94% | $828.41M |
| AMGN | AMGEN INC | 7.92% | $826.53M |
| GILD | GILEAD SCIENCES | 7.38% | $770.82M |
| REGN | REGENERON PHARMACEUTICALS | 5.95% | $621.03M |
| ARGX | ARGENX SE ADR | 3.80% | $396.84M |
| MRNA | MODERNA | 3.60% | $375.46M |
| NTRA | NATERA | 3.29% | $343.72M |
| RVMD | REVOLUTION MEDICINES | 2.89% | $301.29M |
| ALNY | ALNYLAM PHARMACEUTICALS | 2.50% | $261.39M |
| ILMN | ILLUMINA INC | 2.26% | $235.73M |
| BIIB | BIOGEN | 2.25% | $235.03M |
| ONC | BEONE MEDICINES AG | 2.04% | $212.95M |
| INSM | INSMED | 2.02% | $210.71M |
| INCY | INCYTE CORP | 1.82% | $190.06M |
| ROIV | ROIVANT SCIENCES LTD | 1.58% | $164.5M |
| UTHR | UNITED THERAPEUTICS | 1.52% | $158.49M |
| GMAB | GENMAB SPONSORED ADR | 1.26% | $131.5M |
| ASND | ASCENDIS PHARMA | 1.18% | $122.88M |
| NBIX | NEUROCRINE BIOSCIENCES | 1.12% | $116.79M |
| EXEL | EXELIXIS INC | 1.04% | $108.27M |
| MEDP | MEDPACE HOLDINGS | 0.98% | $102.79M |
| CRL | CHARLES RIVER LABORATORIES INTERNA | 0.97% | $100.95M |
| BBIO | BRIDGEBIO PHARMA | 0.94% | $98.02M |
| HALO | HALOZYME THERAPEUTICS | 0.92% | $96.07M |
| BMRN | BIOMARIN PHARMACEUTICAL | 0.90% | $93.41M |
ETF Exposure
Sector and country composition fields from ETF snapshots where available.
| Field | Value |
|---|---|
| Health Care Services | 0.14% |
| Life Sciences Tools & Services | 9.55% |
| Pharmaceuticals | 2.66% |
| Biotechnology | 87.45% |
| Health Care Equipment | 0.10% |
| Cash and/or Derivatives | 0.10% |
| Field | Value |
|---|---|
| United States | 94.28% |
| Australia | 0.08% |
| Spain | 0.13% |
| Switzerland | 0.34% |
| Ireland | 0.10% |
| United Kingdom | 1.54% |
| China | 0.15% |
| Canada | 0.46% |
| Taiwan | 0.00% |
| Denmark | 2.12% |
| Netherlands | 0.29% |
| France | 0.44% |
Institutional Holder Snapshot
Latest downstream filing-reported holders and share-count changes for this ETF.
No downstream institutional holder rows are available for this ETF yet.
Current ETF Metrics
ETF-native fields sit beside technical and risk readings for deeper research.
| Metric | Value |
|---|---|
| Expense Ratio | 0.44% |
| Fund Size | $11.52B |
| NAV | $217.99 |
| Average Volume | 1.64M |
| Beta | 0.7 |
| 52-week high | $222.29 |
| 52-week low | $154.62 |
As of Oct 29, 2026
| Metric | Value |
|---|---|
| Close As of Oct 30, 2026 | $217.61 |
| Volume As of Oct 29, 2026 | 2.84M |
| RSI (14) As of Oct 29, 2026 | 63.29 |
| MACD As of Oct 29, 2026 | 2.19 |
| MACD signal As of Oct 29, 2026 | 0.93 |
| MACD histogram As of Oct 29, 2026 | 1.26 |
| ADX (14) As of Oct 29, 2026 | 12.91 |
| SMA (50) As of Oct 29, 2026 | $208.29 |
| SMA (200) As of Oct 29, 2026 | $184.53 |
| ATR (14) As of Oct 29, 2026 | $4.89 |
| Historical volatility (annualized) As of Oct 29, 2026 | 27.22% |
| Volume (20-day average) As of Oct 29, 2026 | 1.75M |
| Metric | Value |
|---|---|
| Resilience score | 57/100 |
| Beta | 0.7 |
| Annual volatility | 22.81% |
| Max Drawdown | -9.70% |
| Sharpe Ratio | 1.38 |
| VaR (95%, 1-day) | -2.18% |
As of Oct 29, 2026
Additional ETF Metrics
Expanded ETF structure fields appear here when the entitlement and source coverage allow them.
No additional ETF structure metrics are available.
Related Links
IBB ETF Data FAQ
What data matters most for IBB ETF?
IBB ETF data should be read through fund-native fields such as expense ratio, fund size, NAV, holdings, exposure, distribution yield, liquidity, technicals, and risk measures.
Why does IBB not show revenue or EPS?
IBB is an ETF, not an operating company. It does not have company revenue, EPS, margins, or free cash flow; those belong to the underlying holdings, not the fund wrapper.
What does IBB's expense ratio show?
IBB's expense ratio is the annual fund cost when available. It should be compared with fund strategy, income profile, liquidity, and exposure.
How should investors read IBB's holdings data?
IBB's holdings data shows what the fund owns and how concentrated the portfolio is. Holdings weights and sector exposure explain much of the fund's risk and return behavior.
What does IBB's distribution yield mean?
IBB's distribution yield describes the income paid by the ETF over the measured period. It should be read with payout history, fund strategy, fees, and price risk.
Why can ETF profile fields be unavailable?
ETF profile fields can be unavailable when the provider snapshot, serving layer, or entitlement path has not published that field for IBB. Missing ETF fields should remain blank rather than be inferred from stock fundamentals.